Philadelphia, Pennsylvania 19104


This study will describe patient-reported symptom burden and concerns, quality of life (QOL), and health behaviors of breast cancer(BC) survivors who have completed initial treatments (e.g., surgery, chemotherapy, and/or radiotherapy), assess the feasibility of using a web-based platform to collect patient-reported outcome (PRO) data, and evaluate provider satisfaction following delivery of an electronic health record (HER)/EPIC summary of these PROs. Secondary aims will estimate differences in referral to available services between those providers exposed to the PRO summary and historical controls. BC survivors who have completed initial treatment and present within the first year following treatment for an end of treatment (EOT)/survivorship focused visit will be the focus of this study.


Inclusion Criteria: 1. Diagnosed with invasive, non-metastatic BC (Stage I, II, or III) without hematogenous or distant metastases 2. Have completed initial treatment (chemotherapy, radiotherapy, and/or surgery). May still be receiving hormonal or targeted therapy (e.g., tamoxifen, aromatase inhibitors). 3. Within 1 year of completing primary treatment 4. Scheduled for an EOT visit 5. Age 18 years or older 6. Can understand written English 7. Have internet access and a working email address Exclusion Criteria: 1. Diagnosed with non-invasive (Stage 0/DCIS) or metastatic (Stage IV) cancer or hematogenous or distant metastatic disease 2. No working email address -



Primary Contact:

Principal Investigator
Chi Van Dang, MD, PhD
Abramson Cancer Center of the University of Pennsylvania

Linda Jacobs, PhD
Phone: 855-216-0098

Backup Contact:


Location Contact:

Philadelphia, Pennsylvania 19104
United States

Linda Jacobs, PhD
Phone: 855-216-0098

Site Status: Recruiting

Data Source:

Date Processed: November 18, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.